Table 5.
Effects of alfaxalone (10 nM–10 μM) on evoked glycinergic IPSCs.
| Alfaxalone concentration | 1st IPSC amplitude (pA) | 1st IPSC 10%–90% rise-time (ms) | 1st IPSC half-width (ms) | Paired pulse ratio (2nd/1st) | Input resistance (MΩ) | 1st IPSC decay tau (ms) |
|---|---|---|---|---|---|---|
| Control | −217.1 (−340 to −94.2) | 2.5 (1.42–3.6) | 13.5 (9.1–17.9) | 1.3 (1.2–1.4) | 155 (87.3–222.4) | 18 (12.1–24.5) |
| 10 nM | −183.5 (−272.7 to −94.4) | 2.7 (1.7–3.7) | 14.6 (10.7–18.4) | 1.23 (1.1–1.4)* | 148 (87.4–209) | 21 (15.7–26.5) |
| 30 nM | −164.8 (−256.5 to −73.1)* | 3.1 (1.7–4.5)* | 16.1 (11.1–21.1)* | 1.2 (1.1–1.3) | 144 (84–204) | 23 (16–29) |
| 100 nM | −155.2 (−250.2 to −60.1)** | 3.4 (1.6–5.2) | 16.4 (11.7–21.1) | 1.18 (1–1.3) | 144 (90–199) | 24 (17.4–31) |
| 300 nM | −156.4 (−256.3 to −56.5)* | 3.7 (1.5–6) | 16.9 (11.9–21.9)* | 1.15 (1–1.3) | 146 (94–198) | 25 (16.7–32.4) |
| 1 μM | −135.6 (−237.6 to −33.6)*** | 4.4 (2–7) | 16.3 (12.7–20)** | 1.08 (0.9–1.3) | 146 (94.5–198) | 23 (18.5–27.7) |
| 3 μM | −118.1 (−215.8 to −20.4)**** | 4.9 (2.3–7.4)* | 14.3 (9.6–19) | 1.01 (0.8–1.2)* | 165 (105.2–224) | 28 (18.5–37.7) |
| 10 μM | −79.0 (−140.9 to −17.2)**** | 5.8 (3–8.6)** | 9.8 (4.8–14.7) | 0.81 (0.6–1)** | 143 (81.7–204) | 45 (33.1–57.7)**** |
Mean and 95% CI, n = 8 HMNs. Repeated measures ANOVA, Dunnett’s multiple comparisons test. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.